Skip to main content

Table 2 Disease progression and relapses for the intention-to-treat population for whom relapse/EDSS data were available (n=436)

From: Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study

Parameter Number (%) patients
Aged 41–50 years (n=301) Aged >50 years (n=135)
EDSS score:
  improvement (≤–1) 33 (11.0%) 12 (8.9%)
  stable (no change) 219 (72.8%) 90 (66.7%)
  progression (≥+1) 49 (16.3%) 33 (24.4%)
Relapse free throughout the study 272 (90.4%) 127 (94.1%)
Disease-progression freea 252 (83.7%) 102 (75.6%)
Relapse free and disease-progression free 228 (75.7%) 96 (71.1%)
  1. aDisease-progression free defined as EDSS that were stable (change of up to ±1) or improved (at least 1-point decrease) at last patient visit.
  2. EDSS expanded disability status scores.